UK Agency Approves Orladeyo to Prevent HAE Attacks

UK Agency Approves Orladeyo to Prevent HAE Attacks

294190

UK Agency Approves Orladeyo to Prevent HAE Attacks

The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing approval to BioCryst Pharmaceuticals’ Orladeyo (berotralstat), as the first oral and daily therapy to prevent acute attacks of hereditary angioedema (HAE) in individuals ages 12 and older. “HAE UK welcomes the decision from the MHRA to grant marketing authorization for berotralstat in the U.K,” Laura Szutowicz, CEO of HAE U.K., said in a press release. “An oral therapy that shows effective control of…

You must be logged in to read/download the full post.